Stableford Capital II LLC Lowers Stock Holdings in Compass Pathways PLC Sponsored ADR $CMPS

Stableford Capital II LLC lowered its stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 43.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 91,873 shares of the company’s stock after selling 69,266 shares during the period. Stableford Capital II LLC owned approximately 0.07% of Compass Pathways worth $1,300,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Royal Bank of Canada grew its position in Compass Pathways by 49.8% in the 1st quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock valued at $256,000 after buying an additional 29,733 shares during the last quarter. Acadian Asset Management LLC raised its position in Compass Pathways by 42.0% during the 1st quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock worth $686,000 after buying an additional 71,112 shares during the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after acquiring an additional 1,350,698 shares during the period. Balyasny Asset Management L.P. lifted its stake in shares of Compass Pathways by 38.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock worth $2,394,000 after acquiring an additional 235,345 shares during the period. Finally, Northeast Financial Consultants Inc acquired a new stake in shares of Compass Pathways in the 2nd quarter worth $59,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Price Performance

Compass Pathways stock opened at $11.25 on Tuesday. The company has a market cap of $1.52 billion, a P/E ratio of -3.57 and a beta of 2.50. Compass Pathways PLC Sponsored ADR has a one year low of $3.97 and a one year high of $15.40. The business has a fifty day moving average of $12.52 and a two-hundred day moving average of $9.19. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. As a group, analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CMPS. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. HC Wainwright restated a “buy” rating and issued a $70.00 price objective on shares of Compass Pathways in a research report on Wednesday, July 8th. UBS Group set a $18.00 price objective on Compass Pathways in a report on Thursday, May 7th. Stifel Nicolaus boosted their target price on Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.36.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.